Anticancer Drugs Practice Questions

Q: What is the most important target of action of chlorambucil?

Lymphoid tissue. ***Lymphoid tissue*** - **Chlorambucil** is an **alkylating agent** primarily used in the treatment of various **lymphoproliferative disorders**. - Its main therapeutic effect is on rapidly proliferating cells, particularly those of **lymphoid origin**, such as in chronic lymphocytic leukemia (CLL) and other lymphomas. *Myeloid tissue* - While chlorambucil can have some effect on myeloid cells, it is not its primary or most important target; other drugs are more specifically used for **myeloproliferative disorders**. - Its use in conditions like chronic myeloid leukemia (CML) is limited and generally not first-line. *Neural tissue* - Chlorambucil is not primarily an agent targeting **neural tissue** and is not used in the treatment of neurological conditions. - It does not readily cross the **blood-brain barrier** to a significant extent, limiting its direct action on the central nervous system. *Skin* - Although some **lymphomas** can manifest with **cutaneous involvement**, chlorambucil's direct and most important target is not the skin itself but rather the underlying **lymphoid cells**. - It is not a primary treatment for general skin conditions or non-lymphomatous skin cancers.

Q: Which of the following drugs is MOST classically associated with hypomagnesemia?

Cisplatin. ***Cisplatin*** - **Cisplatin** is a platinum-based chemotherapy drug **most classically and severely** associated with **hypomagnesemia** due to **direct renal tubular damage** - Causes significant **magnesium wasting** in the urine through damage to the distal convoluted tubule - This **renal magnesium loss** is a common and often **dose-limiting side effect** of cisplatin therapy - Can persist for **months to years** after treatment and may be **irreversible** *Valproate* - **Valproate** is primarily associated with hepatotoxicity, hyperammonemia, pancreatitis, and teratogenicity - **Not associated** with hypomagnesemia - Its mechanism involves enhancing GABAergic transmission with limited direct renal effects on electrolyte balance *Foscarnet* - **Foscarnet** is an antiviral agent that can cause multiple electrolyte abnormalities including hypocalcemia, hypomagnesemia, and hypokalemia - However, it is **more characteristically associated with hypocalcemia** rather than hypomagnesemia - Works by inhibiting viral DNA polymerase and can chelate divalent cations *Cetuximab* - **Cetuximab**, an EGFR inhibitor, does cause **hypomagnesemia** through increased renal excretion of magnesium (occurs in 10-15% of patients) - However, **cisplatin** is the **more classic and severe** cause due to: - Direct nephrotoxic tubular damage (vs. EGFR-mediated mechanism) - Higher incidence and severity of hypomagnesemia - Longer duration and potential irreversibility - More established in medical literature as the prototypical drug causing this side effect

Q: Imatinib primarily acts by inhibiting which specific target?

BCR–ABL tyrosine kinase. ***BCR–ABL tyrosine kinase*** - Imatinib mesylate is a **specific inhibitor** of the **BCR–ABL tyrosine kinase**, which is the constitutively active oncoprotein found in **chronic myeloid leukemia (CML)**. - Its action involves binding to the ATP-binding site of the kinase domain, thus preventing the **phosphorylation** of downstream substrates required for cell proliferation and survival. *Tyrosine Kinase* - While Imatinib is a **tyrosine kinase inhibitor**, this option is too general as there are many different tyrosine kinases. - The question asks for the **specific target** of Imatinib, which is the BCR-ABL fusion protein's tyrosine kinase activity. *PDGFR* - Imatinib does inhibit **PDGFR (Platelet-Derived Growth Factor Receptor)** tyrosine kinases, which is relevant in some other conditions like gastrointestinal stromal tumors. - However, its primary and most historically significant target, especially in the context of CML that this class of question usually refers to, is the **BCR-ABL fusion protein**. *None of the options* - This option is incorrect because **BCR–ABL tyrosine kinase** is the correct and specific target. - Imatinib's designation as a **tyrosine kinase inhibitor** is due to its action on this specific enzyme.

Q: Bleomycin toxicity affects which organ predominantly?

Lungs. ***Lungs*** - **Bleomycin** is well-known for causing **pulmonary fibrosis**, an irreversible scarring of the lungs, as its most significant and dose-limiting toxicity. - This toxicity is thought to be due to an inability of the lungs to adequately inactivate bleomycin, leading to oxidative damage. *Bone marrow* - While many chemotherapeutic agents cause **bone marrow suppression**, bleomycin is notable for causing **minimal myelosuppression** compared to other cytotoxic drugs. - Therefore, bone marrow is not the predominantly affected organ for toxicity with bleomycin. *Liver* - **Hepatotoxicity** (liver damage) can occur with some chemotherapy agents, but it is **not a primary or prominent toxicity associated with bleomycin**. - Other drugs are much more frequently associated with liver damage. *RBC* - Bleomycin does not directly target **red blood cells (RBCs)** for toxicity. - While severe bone marrow suppression from other drugs can lead to anemia, bleomycin's effect on RBCs is indirect and not its predominant toxicity profile.

Q: Hand foot syndrome is an adverse effect of what?

5-Fluorouracil. ***5-Fluorouracil*** - **Hand-foot syndrome** (**palmar-plantar erythrodysesthesia**) is a common and dose-limiting side effect of 5-Fluorouracil and its prodrug, capecitabine. - It presents with **redness**, **swelling**, **pain**, and **desquamation** of the palms and soles. *Bleomycin* - The primary dose-limiting toxicity of bleomycin is **pulmonary fibrosis**, not hand-foot syndrome. - Other common toxicities include **hyperpigmentation** of the skin and mucocutaneous reactions, but not typically severe palmar-plantar changes. *Etoposide* - Etoposide is associated with adverse effects like **myelosuppression** (leukopenia, thrombocytopenia) and **alopecia**. - While skin reactions can occur, **hand-foot syndrome** is not a characteristic or common side effect of etoposide. *Actinomycin D* - Actinomycin D (dactinomycin) is known for causing **myelosuppression**, **nausea**, **vomiting**, and **mucositis**. - It can also cause **radiation recall phenomenon**, but not typically hand-foot syndrome as a primary or common adverse effect.

Q: What is the mechanism of action of fulvestrant?

Selective estrogen receptor downregulator. ***Selective estrogen receptor downregulator*** - Fulvestrant is classified as a **selective estrogen receptor downregulator (SERD)**. It binds to the estrogen receptor (ER) and promotes its degradation. - This effectively reduces the total number of ERs in the cell nucleus, leading to a profound anti-estrogenic effect without agonist activity. *Selective estrogen agonist* - An estrogen agonist would **activate estrogen receptors**, mimicking the effects of estrogen, which is not the therapeutic goal of fulvestrant in hormone-sensitive cancers. - Such a drug would promote tumor growth in estrogen-sensitive breast cancers. *Selective estrogen receptor modulator* - A selective estrogen receptor modulator (SERM) exhibits **tissue-specific agonist and antagonist effects** (e.g., tamoxifen acts as an antagonist in breast tissue but an agonist in bone). - Fulvestrant, in contrast, is a pure antagonist with no agonist activity and causes receptor degradation. *Selective estrogen receptor upregulator* - An upregulator would **increase the number of estrogen receptors**, potentially making cancer cells more sensitive to estrogen and promoting growth. - This mechanism is contrary to the therapeutic action of fulvestrant, which aims to reduce ER signaling.

Q: Which GnRH agonist is approved for advanced prostate cancer?

Goserelin. ***Goserelin*** - **Goserelin** is a **gonadotropin-releasing hormone (GnRH) agonist** approved for the treatment of **advanced prostate cancer**. - It works by initially stimulating, then desensitizing, the pituitary gland to GnRH, leading to a profound decrease in **luteinizing hormone (LH)** and **follicle-stimulating hormone (FSH)**, which in turn reduces **testosterone production**. - This sustained suppression of testosterone is effective in managing hormone-sensitive prostate cancer. *Abarelix* - **Abarelix** is a **GnRH antagonist** (not an agonist), which directly blocks GnRH receptors. - While it was approved for advanced prostate cancer, it works through a different mechanism (antagonism vs agonism) and was later withdrawn from the market. - It is not a GnRH agonist. *Cetrorelix* - **Cetrorelix** is a **GnRH antagonist** (not an agonist) primarily used in **assisted reproductive technology (ART)** to prevent premature ovulation. - It is not approved for the treatment of prostate cancer. *Ganirelix* - **Ganirelix** is a **GnRH antagonist** (not an agonist) also used in **assisted reproductive technology (ART)** to prevent premature LH surges. - It is not approved for the treatment of prostate cancer.

Q: What is Abraxane?

Albumin-bound formulation of paclitaxel. ***Albumin-bound formulation of paclitaxel*** - **Abraxane** (nab-paclitaxel) is a formulation of **paclitaxel** bound to **albumin nanoparticles**. - This formulation eliminates the need for **Cremophor EL** (used in conventional paclitaxel), thereby avoiding severe **hypersensitivity reactions** and allowing higher doses. - It has improved tumor delivery through albumin-mediated transcytosis. *Globulin-bound formulation of docetaxel* - This is incorrect on **both counts**: Abraxane contains **paclitaxel** (not docetaxel) and uses **albumin** (not globulin). - Docetaxel is formulated with **polysorbate 80**, not with protein carriers. *Albumin-bound formulation of docetaxel* - While the **albumin-bound** concept is correct, the drug is wrong. - Abraxane specifically contains **paclitaxel**, not docetaxel. - Docetaxel does not have an albumin-bound formulation. *Globulin-bound formulation of paclitaxel* - While **paclitaxel** is correct, the carrier protein is wrong. - Abraxane uses **albumin nanoparticles** as the carrier, not globulin. - No globulin-bound taxane formulations are currently available.

Q: Which of the following is not an alkylating agent?

Cladribine. ***Cladribine*** - **Cladribine** is a **purine analog** (antimetabolite), not an alkylating agent, that inhibits DNA synthesis and repair. - It is primarily used in the treatment of **hairy cell leukemia** and certain lymphomas. *Melphalan* - **Melphalan** is an **alkylating agent** derived from nitrogen mustard, used in multiple myeloma and ovarian cancer. - It works by irreversibly binding to DNA, causing **cross-links** and inhibiting DNA replication. *Cyclophosphamide* - **Cyclophosphamide** is a **nitrogen mustard alkylating agent** that forms DNA cross-links and is a prodrug requiring hepatic activation. - It is widely used in various cancers and as an **immunosuppressant**. *Busulfan* - **Busulfan** is an **alkylating agent** specifically a **sulfonate ester**, which cross-links DNA and RNA. - It's mainly used in **myeloproliferative disorders** and as a conditioning agent before stem cell transplantation.

Q: Which of the following anticancer drugs is MOST characteristically associated with pulmonary fibrosis?

Busulfan. ***Busulfan*** - **Busulfan** is an **alkylating agent** that is **MOST characteristically** associated with **pulmonary fibrosis** among the given options. - Causes **"Busulfan lung"** - a distinctive chronic interstitial pulmonary fibrosis that can occur in **4-6% of patients**. - Typically develops **insidiously** after prolonged therapy with **cumulative dose-related toxicity**. - Presents with **progressive dyspnea, dry cough**, and restrictive lung pattern on pulmonary function tests. - This is a **classic association** emphasized in medical examinations. *Cyclophosphamide* - **Cyclophosphamide** can also cause **pulmonary fibrosis**, particularly with high cumulative doses. - However, it is **less characteristically** associated with this complication compared to busulfan. - Pulmonary toxicity is more **variable and less predictable** in severity. *Methotrexate* - **Methotrexate** can cause lung toxicity, most commonly as **acute methotrexate pneumonitis** (hypersensitivity reaction). - While **chronic fibrosis can occur**, it is less frequent than the acute inflammatory process. - Not the **most characteristic** association for pulmonary fibrosis. *Mercaptopurine* - **Mercaptopurine** is an **antimetabolite** primarily associated with **hepatotoxicity** and **myelosuppression**. - **Not associated** with pulmonary fibrosis.

Question 1

What is the most important target of action of chlorambucil?

Accepted Answer

Lymphoid tissue

Answer

Myeloid tissue

Answer

Neural tissue

Answer

Skin

Question 2

Which of the following drugs is MOST classically associated with hypomagnesemia?

Accepted Answer

Cisplatin

Answer

Valproate

Answer

Foscarnet

Answer

Cetuximab

Question 3

Imatinib primarily acts by inhibiting which specific target?

Accepted Answer

BCR–ABL tyrosine kinase

Answer

Tyrosine Kinase

Answer

PDGFR

Answer

None of the options

Question 4

Bleomycin toxicity affects which organ predominantly?

Accepted Answer

Lungs

Answer

Bone marrow

Answer

Liver

Answer

RBC

Question 5

Hand foot syndrome is an adverse effect of what?

Accepted Answer

5-Fluorouracil

Answer

Bleomycin

Answer

Etoposide

Answer

Actinomycin D

Question 6

What is the mechanism of action of fulvestrant?

Accepted Answer

Selective estrogen receptor downregulator

Answer

Selective estrogen agonist

Answer

Selective estrogen receptor modulator

Answer

Selective estrogen receptor upregulator

Question 7

Which GnRH agonist is approved for advanced prostate cancer?

Accepted Answer

Goserelin

Answer

Abarelix

Answer

Cetrorelix

Answer

Ganirelix

Question 8

What is Abraxane?

Accepted Answer

Albumin-bound formulation of paclitaxel

Answer

Globulin-bound formulation of docetaxel

Answer

Albumin-bound formulation of docetaxel

Answer

Globulin-bound formulation of paclitaxel

Question 9

Which of the following is not an alkylating agent?

Accepted Answer

Cladribine

Answer

Cyclophosphamide

Answer

Melphalan

Answer

Busulfan

Question 10

Which of the following anticancer drugs is MOST characteristically associated with pulmonary fibrosis?

Accepted Answer

Busulfan

Answer

Mercaptopurine

Answer

Methotrexate

Answer

Cyclophosphamide

Anticancer Drugs — MCQs

Anticancer Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?